1227089-74-8 Usage
General Description
4,6-Dichloro-1-methyl-1H-pyrazolo[3,4-b]pyridine is a chemical compound that belongs to the pyrazolo[3,4-b]pyridine class. It is a heterocyclic compound that contains a pyrazole and pyridine ring system, with two chlorine atoms and a methyl group attached to the pyrazole ring. This chemical compound has potential applications in the pharmaceutical industry, particularly in the development of novel drugs or pharmaceutical compounds. Its specific properties and potential uses may depend on its exact structure, stability, reactivity, and interactions with biological systems, making it an interesting target for further research and exploration in the field of medicinal chemistry and drug discovery.
Check Digit Verification of cas no
The CAS Registry Mumber 1227089-74-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,7,0,8 and 9 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1227089-74:
(9*1)+(8*2)+(7*2)+(6*7)+(5*0)+(4*8)+(3*9)+(2*7)+(1*4)=158
158 % 10 = 8
So 1227089-74-8 is a valid CAS Registry Number.
1227089-74-8Relevant articles and documents
ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF
-
Paragraph 00499, (2021/07/02)
Provided herein are small molecule modulators of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
-
Page/Page column 54, (2010/07/10)
Compounds of Formula (I), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer or inflammation mediated by lipid kinases. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
